Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro.

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI:10.20517/cdr.2024.50
Shruti Vig, Payal Srivastava, Idrisa Rahman, Renee Jaranson, Anika Dasgupta, Robert Perttilä, Petteri Uusimaa, Huang-Chiao Huang
{"title":"Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions <i>in vitro</i>.","authors":"Shruti Vig, Payal Srivastava, Idrisa Rahman, Renee Jaranson, Anika Dasgupta, Robert Perttilä, Petteri Uusimaa, Huang-Chiao Huang","doi":"10.20517/cdr.2024.50","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> ATP-binding cassette (ABC) transporters are proteins responsible for the efflux of drug molecules from cancer cells, reducing the efficacy of anti-cancer treatments. This study assesses the susceptibility of a panel of clinically used photosensitizers to be transported by ABC transporters <i>in vitro.</i> <b>Methods:</b> The involvement of P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated protein 1 (MRP1/ABCC1) in the transport of 7 clinically utilized photosensitizers [benzoporphyrin derivative (BPD), temoporfin, redaporfin, talaporfin sodium, rose bengal, methylene blue, and indocyanine green] were investigated using human breast cancer cell lines following well-established protocols. Briefly, parental MCF-7 cells and sublines that overexpress P-gp (MCF-7 TX400), ABCG2 (MCF-7 MX100), or MRP1 (MCF-7/VP) were treated with photosensitizers with and without ABC transporter inhibitors. Intracellular levels of photosensitizers were measured using extraction method and flow cytometry to determine whether the ABC transporters are associated with efflux or uptake of photosensitizers. <b>Results:</b> The ABCG2 inhibitor (fumitremorgin C) and P-gp inhibitor (valspodar) effectively blocked the transport mediated by ABCG2 and P-gp of rose bengal and BPD. Redaporfin showed increased accumulation in the presence of valspodar with flow cytometry. Interestingly, MCF-7/VP cells were found to have reduced intracellular accumulation of rose bengal, which was restored with MRP1 inhibitor (MK571). The cell viability assay showed photodynamic therapy (PDT) resistance with Redaporfin in P-gp-overexpressing cells, BPD in ABCG2- and P-gp-overexpressing cells, and with Rose bengal in ABCG2-, P-gp- and MRP1-overexpressing cells, respectively. However, no change in intracellular retention was observed for other photosensitizers. <b>Conclusion:</b> In summary, our study provided new knowledge that temoporfin, talaporfin sodium, methylene blue, and indocyanine green are not substrates of ABCG2, P-gp, or MRP1. Redaporfin is a substrate for P-gp. BPD is a known substrate of ABCG2 and P-gp. Rose bengal is a substrate of ABCG2, P-gp, and MRP1. The results presented here indicate ABC transporter substrate status as a possible cause for cellular resistance to photodynamic therapy with rose bengal, redaporfin, and BPD.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"35"},"PeriodicalIF":4.6000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472579/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/cdr.2024.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: ATP-binding cassette (ABC) transporters are proteins responsible for the efflux of drug molecules from cancer cells, reducing the efficacy of anti-cancer treatments. This study assesses the susceptibility of a panel of clinically used photosensitizers to be transported by ABC transporters in vitro. Methods: The involvement of P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated protein 1 (MRP1/ABCC1) in the transport of 7 clinically utilized photosensitizers [benzoporphyrin derivative (BPD), temoporfin, redaporfin, talaporfin sodium, rose bengal, methylene blue, and indocyanine green] were investigated using human breast cancer cell lines following well-established protocols. Briefly, parental MCF-7 cells and sublines that overexpress P-gp (MCF-7 TX400), ABCG2 (MCF-7 MX100), or MRP1 (MCF-7/VP) were treated with photosensitizers with and without ABC transporter inhibitors. Intracellular levels of photosensitizers were measured using extraction method and flow cytometry to determine whether the ABC transporters are associated with efflux or uptake of photosensitizers. Results: The ABCG2 inhibitor (fumitremorgin C) and P-gp inhibitor (valspodar) effectively blocked the transport mediated by ABCG2 and P-gp of rose bengal and BPD. Redaporfin showed increased accumulation in the presence of valspodar with flow cytometry. Interestingly, MCF-7/VP cells were found to have reduced intracellular accumulation of rose bengal, which was restored with MRP1 inhibitor (MK571). The cell viability assay showed photodynamic therapy (PDT) resistance with Redaporfin in P-gp-overexpressing cells, BPD in ABCG2- and P-gp-overexpressing cells, and with Rose bengal in ABCG2-, P-gp- and MRP1-overexpressing cells, respectively. However, no change in intracellular retention was observed for other photosensitizers. Conclusion: In summary, our study provided new knowledge that temoporfin, talaporfin sodium, methylene blue, and indocyanine green are not substrates of ABCG2, P-gp, or MRP1. Redaporfin is a substrate for P-gp. BPD is a known substrate of ABCG2 and P-gp. Rose bengal is a substrate of ABCG2, P-gp, and MRP1. The results presented here indicate ABC transporter substrate status as a possible cause for cellular resistance to photodynamic therapy with rose bengal, redaporfin, and BPD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在体外筛选光敏剂-ATP 结合盒 (ABC) 转运体之间的相互作用。
目的:ATP 结合盒(ABC)转运体是一种蛋白质,负责将药物分子从癌细胞中排出,从而降低抗癌治疗的疗效。本研究评估了一组临床使用的光敏剂在体外被 ABC 转运体转运的敏感性。方法:采用人乳腺癌细胞系,按照成熟的方案研究了 P-糖蛋白(P-gp/ABCB1)、乳腺癌抗性蛋白(BCRP/ABCG2)和多药耐药性相关蛋白 1(MRP1/ABCC1)参与 7 种临床常用光敏剂[苯并卟啉衍生物(BPD)、替莫卟吩、瑞达泊芬、他拉泊芬钠、玫瑰红、亚甲蓝和吲哚菁绿]转运的情况。简而言之,亲代 MCF-7 细胞和过表达 P-gp(MCF-7 TX400)、ABCG2(MCF-7 MX100)或 MRP1(MCF-7/VP)的亚系细胞在使用或不使用 ABC 转运体抑制剂的情况下用光敏剂处理。使用萃取法和流式细胞术测量细胞内光敏剂的水平,以确定 ABC 转运体是否与光敏剂的外流或吸收有关。结果ABCG2抑制剂(fumitremorgin C)和P-gp抑制剂(valspodar)能有效阻断玫瑰红和BPD在ABCG2和P-gp介导下的转运。流式细胞术显示,在 valspodar 的存在下,Redaporfin 的积累增加。有趣的是,MCF-7/VP 细胞发现玫瑰红素在细胞内的蓄积减少了,而使用 MRP1 抑制剂(MK571)后又恢复了。细胞活力测定显示,P-gp 基因过表达细胞对 Redaporfin 的光动力疗法(PDT)耐药,ABCG2-和 P-gp 基因过表达细胞对 BPD 的光动力疗法耐药,ABCG2-、P-gp-和 MRP1 基因过表达细胞对玫瑰红的光动力疗法耐药。然而,其他光敏剂在细胞内的保留时间没有变化。结论总之,我们的研究提供了新的知识,即替莫泊芬、他拉泊芬钠、亚甲基蓝和吲哚菁绿不是 ABCG2、P-gp 或 MRP1 的底物。雷达波芬是 P-gp 的底物。BPD 是 ABCG2 和 P-gp 的已知底物。玫瑰红是 ABCG2、P-gp 和 MRP1 的底物。本文的研究结果表明,ABC 转运体底物状态可能是导致细胞对玫瑰红、redaporfin 和 BPD 光动力疗法产生耐药性的原因之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. NFE2L2 and ferroptosis resistance in cancer therapy. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1